Press Releases April 30, 2026 04:05 PM

Swarmer Announces Date for First Quarter 2026 Results and Business Updates

Swarmer schedules Q1 2026 earnings call highlighting ongoing deployment in Ukraine

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
SWMR

Swarmer, Inc, a Nasdaq-listed drone autonomy software company, announced its Q1 2026 earnings release and conference call scheduled for May 13, 2026. The company supports drone operations in Ukraine and has completed over 100,000 combat missions. Swarmer provides autonomous swarm coordination and AI-powered control software primarily licensed to drone manufacturers.

Swarmer Announces Date for First Quarter 2026 Results and Business Updates
SWMR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Swarmer to release Q1 2026 financial results and hold earnings call on May 13, 2026.
  • Company's software has supported more than 100,000 combat missions in Ukraine since April 2024, validating its technology in real-world military operations.
  • Swarmer focuses on autonomous swarm coordination and AI integration for multi-domain unmanned systems, with customers primarily drone manufacturers.

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Swarmer, Inc (“Swarmer”) (Nasdaq: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, will hold a conference call and webcast on Wednesday, May 13, 2026, at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) to discuss its financial results for the quarter ended March 31, 2026. Financial results will be issued in a press release prior to the call.

Swarmer management will host the presentation, followed by a question-and-answer period.

Date: Wednesday, May 13, 2026
Time: 9:00 a.m. ET (6:00 a.m. PT)
Toll-Free Number: 877-407-6184
International Number: +1 201-389-0877
Webcast: Register and Join

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

The conference call will be broadcast simultaneously and available for webcast replay here.

About Swarmer
Swarmer™ is a defense technology company that specializes in vendor-agnostic technologies that address critical operational challenges faced by modern military forces. Swarmer’s primary mission areas include autonomous swarm coordination, multi-domain unmanned systems integration, AI-powered collaborative autonomy, and command and control software for distributed operations. The company’s primary customer base consists of drone manufacturers who license Swarmer’s software for integration with their hardware platforms. Swarmer’s technology has been rigorously validated in real-world kinetic environments and was first deployed in combat operations in Ukraine in April 2024. Since then, it has completed more than 100,000 combat missions, generating terabytes of proprietary data that informs its machine-learning models and enables the replication of advanced pilot performance at scale. With headquarters in Austin, Texas, Swarmer has offices in the U.S, Ukraine, Poland and Estonia.

Investor Relations Contact: SWMR@gateway-grp.com

Media Relations Contact: media@swarmer.tech


Risks

  • Reliance on continued military deployments and defense contracts, which can be subject to geopolitical shifts and budget changes.
  • Technological risks related to maintaining a competitive edge in autonomous drone software in a rapidly evolving defense technology sector.
  • Uncertainties regarding future operational environments and regulatory considerations that could affect the deployment and adoption of drone autonomy software.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026